Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043
dc.contributor.author | Zakharia, Y | |
dc.contributor.author | Singer, EA | |
dc.contributor.author | Acharyya, S | |
dc.contributor.author | Garje, R | |
dc.contributor.author | Joshi, M | |
dc.contributor.author | Peace, D | |
dc.contributor.author | Baladandayuthapani, V | |
dc.contributor.author | Majumdar, A | |
dc.contributor.author | Li, X | |
dc.contributor.author | Lalancette, C | |
dc.contributor.author | Kryczek, I | |
dc.contributor.author | Zou, W | |
dc.contributor.author | Alva, A | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-08-12T18:30:50Z | |
dc.date.available | 2024-08-12T18:30:50Z | |
dc.date.issued | 2024-12-01 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/38302476 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/194305 | en |
dc.description.abstract | Epigenetic modulation is well established in hematologic malignancies but to a lesser degree in solid tumors. Here we report the results of a phase Ib/II study of guadecitabine and durvalumab in advanced clear cell renal cell carcinoma (ccRCC; NCT03308396). Patients received guadecitabine (starting at 60 mg/m2 subcutaneously on days 1-5 with de-escalation to 45 mg/m2 in case of dose limiting toxicity) with durvalumab (1500 mg intravenously on day 8). The study enrolled 57 patients, 6 in phase Ib with safety being the primary objective and 51in phase II, comprising 2 cohorts: 36 patients in Cohort 1 were treatment naive to checkpoint inhibitors (CPI) with 0-1 prior therapies and 15 patients in Cohort 2 were treated with up to two prior systemic therapies including one CPI. The combination of guadecitabine 45 mg/m2 with durvalumab 1500 mg was deemed safe. The primary objective of overall response rate (ORR) in cohort 1 was 22%. Sixteen patients (44%) experienced stable disease (SD). Secondary objectives included overall survival (OS), duration of response, progression-free survival (PFS), clinical benefit rate, and safety as well as ORR for Cohort 2. Median PFS for cohort 1 and cohort 2 were 14.26 and 3.91 months respectively. Median OS was not reached. In cohort 2, one patient achieved a partial response and 60% achieved SD. Asymptomatic neutropenia was the most common adverse event. Even though the trial did not meet the primary objective in cohort 1, the tolerability and PFS signal in CPI naive patients are worth further investigation. | |
dc.format.medium | Electronic | |
dc.language | eng | |
dc.publisher | Springer Nature | |
dc.relation.haspart | 972 | |
dc.rights | Licence for published version: Creative Commons Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Humans | |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Azacitidine | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Antibodies, Monoclonal | |
dc.title | Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043 | |
dc.type | Article | |
dc.identifier.pmid | 38302476 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/194305/2/Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma results from the phase IbII study BTCRC-GU16-043.pdf | |
dc.identifier.doi | 10.1038/s41467-024-45216-z | |
dc.identifier.doi | https://dx.doi.org/10.7302/23654 | |
dc.identifier.source | Nature Communications | |
dc.description.version | Accepted version | |
dc.date.updated | 2024-08-12T18:30:47Z | |
dc.identifier.orcid | 0000-0001-9480-2626 | |
dc.identifier.orcid | 0000-0002-9403-760X | |
dc.identifier.orcid | 0000-0002-6854-4034 | |
dc.identifier.orcid | 0000-0002-3130-2533 | |
dc.identifier.orcid | 0000-0001-7952-3549 | |
dc.identifier.orcid | 0000-0002-1898-3522 | |
dc.identifier.volume | 15 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 972 | |
dc.identifier.name-orcid | Zakharia, Y; 0000-0001-9480-2626 | |
dc.identifier.name-orcid | Singer, EA | |
dc.identifier.name-orcid | Acharyya, S | |
dc.identifier.name-orcid | Garje, R | |
dc.identifier.name-orcid | Joshi, M | |
dc.identifier.name-orcid | Peace, D; 0000-0002-9403-760X | |
dc.identifier.name-orcid | Baladandayuthapani, V | |
dc.identifier.name-orcid | Majumdar, A | |
dc.identifier.name-orcid | Li, X | |
dc.identifier.name-orcid | Lalancette, C; 0000-0002-6854-4034 | |
dc.identifier.name-orcid | Kryczek, I; 0000-0002-3130-2533 | |
dc.identifier.name-orcid | Zou, W; 0000-0001-7952-3549 | |
dc.identifier.name-orcid | Alva, A; 0000-0002-1898-3522 | |
dc.working.doi | 10.7302/23654 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.